DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Rating of “Moderate Buy” by Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $12.3333.

A number of analysts have recently commented on DMAC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th.

DiaMedica Therapeutics Stock Down 4.2%

Shares of DMAC stock opened at $5.96 on Thursday. The company’s fifty day simple moving average is $7.05 and its 200-day simple moving average is $7.57. The firm has a market cap of $321.14 million, a PE ratio of -8.51 and a beta of 1.16. DiaMedica Therapeutics has a 12 month low of $3.47 and a 12 month high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $13.50 million. On average, equities analysts predict that DiaMedica Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter worth $29,000. Russell Investments Group Ltd. acquired a new position in DiaMedica Therapeutics during the third quarter worth $27,000. Farther Finance Advisors LLC acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $34,000. Bank of America Corp DE increased its holdings in DiaMedica Therapeutics by 3,710.3% during the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after buying an additional 8,274 shares during the last quarter. Finally, Strs Ohio increased its holdings in DiaMedica Therapeutics by 19.7% during the third quarter. Strs Ohio now owns 9,100 shares of the company’s stock worth $63,000 after buying an additional 1,500 shares during the last quarter. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.